In patients with BC, tumor-associated macrophages (TAMs) can account for up to 50% of the tumor weight [6], with a high intra-tumoral density of M2-like macrophages (typically CD163+) being positively correlated to larger tumor size, unfavorable prognostic factors (e.g., higher grade, proliferating index, hormone receptor negativity) and reduced survival [7,8,9,10]. This evidence concerns the gene NR4A1 and neoplasm.